ClinicalTrials.gg
TerminatedNCT00260208Updated Dec 6, 2011Results posted

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

A Phase 4 interventional study of Cyclosporine A and Tacrolimus in Liver Transplant and Hepatitis C, sponsored by Novartis Pharmaceuticals. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-12-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Prevention

Why this study was terminated
Study was prematurely terminated due to poor recruitment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
361
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies in Hepatitis C by Novartis — none open to participants now, none under way, none of them phase 3. Hepatitis C · Novartis.

Started
2006
the only one that year
Phase 4
2 of 10
none open now
Registered
2nd of 10
by date

Among the 10 studies in Hepatitis C by Novartis, this one is the only one that started in 2006, is one of 2 in phase 4, and was the 2nd registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 10 studies in Hepatitis C by Novartis is open now. The open studies under Hepatitis C, anywhere →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Hepatitis C by Novartis as a file.
02

Study summary

Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver. The aim of this study was to see if the frequency of liver fibrosis was different with cyclosporine microemulsion than tacrolimus

03

Conditions studied

  • Liver Transplant
  • Hepatitis C

Keywords

  • Liver transplant, adults, hepatitis C, liver fibrosis, cyclosporine microemulsion, tacrolimus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reason for transplant is end-stage liver disease due to cirrhosis
  • Patients receiving a first liver transplant from a deceased or living donor
  • Patients in whom will be possible

Exclusion criteria

Exclusion criteria

  • Recipients of a liver from an virus positive (HCV+), positive (HIV+) or virus positive (HBV+) donor
  • Patients with any severe coexisting disease or suffering any unstable medical condition or co-infected with HBV or HIV
  • Patients with co-existing alcoholic disease who have not been abstinent for at least 6 months
  • Transplanted for liver cancer exceeding a pre-defined size
  • Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
361 participants (actual)

Study arms

  • Active comparator
    Cyclosporin A

    The first administration of Cyclosporin A (CsA) was within the first 24 hours post-transplantation at an initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout the study period. During the study, the dose of CsA was adjusted, as necessary, to achieve and maintain the C2 or C0 blood CsA concentration within the target ranges. Before enrolling the first patient, each center chose the adjunct immunosuppressive (IS) regimen between: * Steroids administered and tapered as per local practice * interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice. The regimen selected by the center was to be given to all patients enrolled in the trial from this center.

    Drug: Cyclosporine A

  • Active comparator
    Tacrolimus

    Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses (twice daily at 12-hour interval) either orally or via a nasogastric (NG) tube or intravenously (i.v). Twice daily (b.i.d.) administration was maintained throughout study period. Throughout the study, the dose of tacrolimus was adjusted as necessary to achieve and maintain C0 tacrolimus concentrations within target ranges. Before enrolling the first patient, each center chose adjunct immunosuppressive (IS) regimen between: * Steroids administered and tapered as per local practice * interleukin-2 receptor (IL-2R) antagonists + mycophenolic acid (MPA): Induction with IL-2R antagonists; Dosages were as per center practice. Patients received mycophenolic acid (MPA) no later than 24 hours after reperfusion of the graft. Dosages were as per local practice. The regimen selected by center was to be given to all patients enrolled in trial from this center.

    Drug: Tacrolimus

Interventions

  • Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.

    Also known as: Neoral

  • Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant

    Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. Logistic regression on the presence of IK\>=2 was applied based on central biopsy readings only.

    Time frame: 1 year post-transplant

Secondary outcomes

  1. Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2

    The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) ≥2 was calculated. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died. Assessment of hepatic fibrosis was performed with liver biopsies read centrally. Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis. Higher score indicates greater fibrosis.

    Time frame: 1 year post-transplant

  2. Number of Participants With Fibrosing Cholestatic Hepatitis

    Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well. The presence of FCH was reported based on the diagnosis given by the investigator.

    Time frame: 1 year post-transplantation

  3. Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation

    Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.

    Time frame: 1 year post-transplant

  4. Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection

    Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy. BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection.

    Time frame: 1 year post-transplant

  5. Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)

    BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.

    Time frame: 1 year post-transplant

  6. Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis

    Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver.

    Time frame: 1 year post-transplant

  7. Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)

    Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis.

    Time frame: 1 year post-transplant

  8. Mean Value of Liver Function Tests at 1 Year Post-transplantation

    The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant: * Serum glutamic pyruvic transaminase (SGPT) * Serum Glutamic Oxaloacetic Transaminase (SGOT) * Bilirubin * Alkaline Phosphate * γ-Glutamyltransferase (GGT)

    Time frame: 1 year post-transplant

  9. Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant

    HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed.

    Time frame: Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant

  10. Percentage of Participants With an Increase of at Least 1 Stage in Fibrosis

    Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. An increase of at least 1 stage demonstrated a worsening of the disease, i.e. the transition from one score to the next higher one.

    Time frame: Between 1 and 2 years

  11. Mean Fibrosis Score

    Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. The mean score was equivalent to mean of IK at 1 and 2 years (evolution over time).

    Time frame: At 1and 2 years and its evolution over time

07

Results

Posted Oct 26, 2011
Limitations and caveats
This study was prematurely discontinued due to poor recruitment. Since only a small patient group could be analyzed for primary outcome measure, robust conclusions on the effect of the two calcineurin inhibitors on the fibrosis score cannot be drawn.

Participant flow

Participant flow — Overall Study
MilestoneCyclosporin ATacrolimus
Started184172
Intent to treat (itt) population182169
Modified itt10196
Completed137138
Not completed4734
Withdrew: Subject withdrew consent117
Withdrew: Lost to follow-up61
Withdrew: Death1210
Withdrew: Missing1816

Outcome measures

PrimaryNumber of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant

Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. Logistic regression on the presence of IK\>=2 was applied based on central biopsy readings only.

Time frame:
1 year post-transplant
Reported as:
Number · Participants
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant
ParticipantsCyclosporin ATacrolimus
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant6352
SecondaryNumber of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2

The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) ≥2 was calculated. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died. Assessment of hepatic fibrosis was performed with liver biopsies read centrally. Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis. Higher score indicates greater fibrosis.

Time frame:
1 year post-transplant
Reported as:
Number · Participants
Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2
ParticipantsCyclosporin ATacrolimus
Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 27771
SecondaryNumber of Participants With Fibrosing Cholestatic Hepatitis

Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well. The presence of FCH was reported based on the diagnosis given by the investigator.

Time frame:
1 year post-transplantation
Reported as:
Number · Participants
Number of Participants With Fibrosing Cholestatic Hepatitis
ParticipantsCyclosporin ATacrolimus
Number of Participants With Fibrosing Cholestatic Hepatitis96
SecondaryNumber of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation

Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.

Time frame:
1 year post-transplant
Reported as:
Number · Participants
Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation
ParticipantsCyclosporin ATacrolimus
Death1515
Graft loss813
Death or Graft loss1923
Graft loss with re-transplantation38
SecondaryNumber of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection

Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy. BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection.

Time frame:
1 year post-transplant
Reported as:
Number · Participants
Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection
ParticipantsCyclosporin ATacrolimus
Treated acute rejection2822
Biopsy prove acute rejection (BPAR)2819
Sub-clinical rejection44
SecondaryNumber of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)

BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.

Time frame:
1 year post-transplant
Reported as:
Number · Participants
Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)
ParticipantsCyclosporin ATacrolimus
Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)4542
SecondaryNumber of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis

Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver.

Time frame:
1 year post-transplant
Reported as:
Number · Participants
Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis
ParticipantsCyclosporin ATacrolimus
Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis1617
SecondaryNumber of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)

Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis.

Time frame:
1 year post-transplant
Reported as:
Number · Participants
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)
ParticipantsCyclosporin ATacrolimus
Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)6354
SecondaryMean Value of Liver Function Tests at 1 Year Post-transplantation

The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant: * Serum glutamic pyruvic transaminase (SGPT) * Serum Glutamic Oxaloacetic Transaminase (SGOT) * Bilirubin * Alkaline Phosphate * γ-Glutamyltransferase (GGT)

Time frame:
1 year post-transplant
Reported as:
Mean · IU/L
Mean Value of Liver Function Tests at 1 Year Post-transplantation
IU/LCyclosporin ATacrolimus
SGPT (n= 112, 112)100.5 ± 178.881.7 ± 82.5
SGOT (n= 112,112)92.0 ± 122.372.8 ± 98.2
Bilirubin (n= 111, 115)40.3 ± 85.519.3 ± 27.9
Alkaline Phosphate (n= 111, 115)174.7 ± 152.9152.9 ± 127.3
GGT (n= 103, 110)182.2 ± 224.3168.5 ± 278.7
SecondaryLog-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant

HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed.

Time frame:
Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant
Reported as:
Mean · IU/µL
Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant
IU/µLCyclosporin ATacrolimus
Day 1 (n=116, 111)0.71 ± 0.8870.62 ± 0.809
Day 3 (n= 136, 120)0.98 ± 1.1120.91 ± 1.024
Day 8 (n= 122, 117)1.58 ± 1.5691.45 ± 1.557
Day 29 (n=128, 109)2.56 ± 1.6582.74 ± 1.439
Month 6 (n=96, 98)3.45 ± 1.0693.14 ± 1.332
Month 12 (n= 85, 88)3.17 ± 1.2463.13 ± 1.385
SecondaryPercentage of Participants With an Increase of at Least 1 Stage in Fibrosis

Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. An increase of at least 1 stage demonstrated a worsening of the disease, i.e. the transition from one score to the next higher one.

Time frame:
Between 1 and 2 years
Reported as:
Number · Percentage of participants

No measurements were reported for this outcome.

SecondaryMean Fibrosis Score

Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. The mean score was equivalent to mean of IK at 1 and 2 years (evolution over time).

Time frame:
At 1and 2 years and its evolution over time
Reported as:
Mean · units on a scale

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclosporin A—148/184 (80.4%)182/184 (98.9%)
Tacrolimus—138/172 (80.2%)167/172 (97.1%)
Most frequent serious events
Showing 10 of 232
Most frequent serious events
EventCyclosporin ATacrolimus
Hepatitis CInfections and infestations77/18465/172
Liver function test abnormalInvestigations14/1849/172
Renal failure acuteRenal and urinary disorders14/1846/172
PyrexiaGeneral disorders13/1849/172
Liver transplant rejectionImmune system disorders11/1847/172
Complications of transplanted liverInjury, poisoning and procedural complications3/18410/172
Abdominal painGastrointestinal disorders3/1849/172
CholangitisHepatobiliary disorders9/1842/172
Bile duct stenosisHepatobiliary disorders8/1843/172
SepsisInfections and infestations8/1845/172
Most frequent other events
Showing 10 of 74
Most frequent other events
EventCyclosporin ATacrolimus
HypertensionVascular disorders92/18469/172
InsomniaPsychiatric disorders65/18464/172
ConstipationGastrointestinal disorders64/18462/172
NauseaGastrointestinal disorders55/18459/172
Procedural painInjury, poisoning and procedural complications50/18459/172
Oedema peripheralGeneral disorders61/18458/172
DiarrhoeaGastrointestinal disorders41/18457/172
AnaemiaBlood and lymphatic system disorders51/18454/172
HyperglycaemiaMetabolism and nutrition disorders46/18449/172
PyrexiaGeneral disorders52/18447/172

Baseline characteristics

Age Continuous
Age Continuous(years)Cyclosporin ATacrolimusTotal
Mean54.4 ± 6.954.4 ± 7.154.4 ± 7.0
Age, Customized
Age, Customized(Participants)Cyclosporin ATacrolimusTotal
< 65 years163154317
≥ 65 years191534
Sex: Female, Male
Sex: Female, Male(Participants)Cyclosporin ATacrolimusTotal
Female5748105
Male125121246
08

Study locations

2 sites
  • Novartis Investigative Site
    East Hanover, New Jersey, United States
  • Novartis Investigational Site
    Zurich, 8091, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006 and a primary completion of Sep 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2005
First posted
Dec 1, 2005
Start
Jan 2006
Primary completionActual
Sep 2010
Results first posted
Oct 26, 2011
Last update
Dec 6, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00260208
Responsible party
Sponsor
First posted
Dec 1, 2005
Start date
Jan 2006
Primary completion
Sep 2010
Results posted
Oct 26, 2011
Last update
Dec 6, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclosporine · Tacrolimus

Start the discussion